Bristol-Myers to file for OTC sale of its Pravachol statin

12/13/2004 | Wall Street Journal, The

Bristol-Myers Squibb has taken official action to get FDA approval to sell its cholesterol-lowering Pravachol over the counter, possibly paving the way for OTC versions of other statins. Bristol-Myers faces the loss of its patent on Pravachol in just over a year and OTC sales are seen as opening a new market for the drugs. An FDA advisory panel plans to meet in mid-January on a similar request by Merck for Mevacor.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT